#Sustainability #India #Mumbai #SP Global #Piramal Pharma

Piramal Pharma Achieves Remarkable Score Improvement in 2025 S&P Global CSA

Piramal Pharma Limited (PPL) has made headlines with its outstanding performance in the S&P Global Corporate Sustainability Assessment (CSA) for 2025. Achieving a score of 63, the company has marked a significant improvement. This score places PPL in the 91st percentile of the pharmaceutical industry, highlighting its commitment to sustainable business practices.

The S&P Global CSA is a prestigious annual assessment that evaluates the sustainability practices of thousands of companies across various industries, making it one of the most respected benchmarks for corporate sustainability worldwide. PPL’s score represents a notable 15% increase compared to the previous year's score of 55, underscoring the company's ongoing dedication to responsible operations and sustainability.

In a statement, PPL expressed pride in reaching this impressive milestone, which reflects the organization's strategic approach to sustainability. The four pillars of PPL's sustainability strategy include business resilience, quality and excellence, responsible governance, and stakeholder engagement. By enhancing its performance in these critical areas, PPL reaffirms its commitment to responsible practices that benefit its partners, patients, and the planet.

One key initiative supporting this achievement is the installation of a rooftop solar system at the company’s facility, operational since April 2024. This 240 kWp system has produced approximately 607 GJ of renewable energy in FY2025, resulting in a substantial reduction of 123 tonnes of CO₂ emissions. Such initiatives greatly contribute to PPL’s goal of expanding its clean energy use and minimizing its environmental impact.

This year's remarkable progress serves as a testament to PPL's steadfast dedication to sustainability. CEO Peter DeYoung remarked, "Our advancements in the S&P Global CSA underscore our unwavering commitment to responsible operations and sustainable growth. As we continue to expand, we remain devoted to excellence in every aspect of our work, ensuring our contributions lead to a healthier future for all."

The S&P Global CSA analysis not only assesses the environmental, social, and governance (ESG) performance of companies but also evaluates their governance maturity and long-term value creation capabilities. A higher score not only strengthens customer trust but significantly enhances a company’s reputation with global investors.

Piramal Pharma operates through 17 manufacturing and development sites around the world and serves over 100 countries, providing a diverse portfolio of products and services. This includes Piramal Pharma Solutions, a leading contract development and manufacturing organization (CDMO), and Piramal Critical Care, known for complex hospital generics. Moreover, its partnership with Abbvie Therapeutics India Private Limited has made significant strides in the ophthalmic segment of the Indian pharmaceutical market.

PPL's strategic initiatives and commitment to sustainability not only mark a stellar performance in assessments like the S&P Global CSA but also reflect its broader ambition to influence positive change and lead in the field of sustainable pharmaceuticals. As the company continues on this trajectory, it seeks to reinforce its partnerships and drive impactful changes in the healthcare sector.